NCT01333813View on ClinicalTrials.gov

Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

April 26, 2011

Primary Completion Date

September 28, 2011

Study Completion Date

September 28, 2011

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Engerix-B™ Kinder

Intramuscular, single dose

Trial Locations (12)

13055

GSK Investigational Site, Berlin

34225

GSK Investigational Site, Braunatal

48163

GSK Investigational Site, Münster

67227

GSK Investigational Site, Frankenthal

67547

GSK Investigational Site, Worms

70469

GSK Investigational Site, Stuttgart

71720

GSK Investigational Site, Oberstenfeld

77694

GSK Investigational Site, Kehl

78532

GSK Investigational Site, Tuttlingen

87435

GSK Investigational Site, Kempten (Allgäu)

88348

GSK Investigational Site, Bad Saulgau

95463

GSK Investigational Site, Bindlach

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01333813 - Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children | Biotech Hunter | Biotech Hunter